Full Press Release Details
Published Results from Sagimet's FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640's Ability to Significantly Reduce Excess Liver Fat.
SGMT
Published Results from Sagimet's FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640's Ability to Significantly Reduce Excess Liver Fat
Key Takeaway: Published Results from Sagimet's FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640's Ability to Significantly Reduce Excess Liver Fat
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease